Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | G6PD | P11413 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Helicide SCHEMBL5030879 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL17822698 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL467669 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL9426962 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| Helicide SCHEMBL987981 | 1.00 | TYR (0.69) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL6842994 | 0.99 | TYR (0.67) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL6842995 | 0.99 | TYR (0.67) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL9189048 | 0.88 | KDM4E (0.59) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL16785945 | 0.88 | TYR (0.87) | TYRKDM4EPOLBGAAMAPT | |
| SCHEMBL17366540 | 0.88 | TYR (0.87) | TYRKDM4EPOLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | ABBVIE INC. | 2021-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171637-A1 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | HRH3, H1-3, CD274 | TYR 2716/4885KDM4E 424/4885POLB 4696/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.